Biolife Science, Imugene deal

Drug delivery company Imugene will acquire Biolife for 300 million shares of Imugene stock, or about A$3.6 million ($3.5 million) based on Imugene's close of A$0.012 on Oct. 18, before the deal was announced. Imugene gains Biolife's HER-Vaxx, a vaccine directed against HER2 receptor consisting of B cell peptides derived from the extracellular domain of HER2. HER-Vaxx completed a Phase I trial in breast cancer, with Phase II testing in gastric cancer slated to start in 2015. ...